REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen

DRUG4 trials

Sponsors

Ferring Pharmaceuticals A/S, Santiago Dexeus Font Fundacio Privada, Universitair Ziekenhuis Brussel

Conditions

Idiopathic male infertility (including oligoasthenozoospermia).InfertilityInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleVolutary women who wish to donate their oocytes

Phase 2

A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility

CompletedCTIS2023-508430-34-00

Ferring Pharmaceuticals A/SIdiopathic male infertility (including oligoasthenozoospermia).

Start: 2023-01-12End: 2024-10-23Target: 197Updated: 2024-10-16

Phase 3

A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme

Not yet recruitingCTIS2022-500308-23-00

Ferring Pharmaceuticals A/SInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle

Target: 115Updated: 2022-11-09

Phase 4

The impact of ovarian stimulation intensity on embryo euploidy in advanced age women. A randomized controlled trial

RecruitingCTIS2023-507028-22-00

Santiago Dexeus Font Fundacio PrivadaInfertility

Start: 2023-12-12Target: 110Updated: 2024-07-04

Luteal phase ovarian stimulation with Follitropin delta and dydrogesterone: a randomized cross over pilot trial

RecruitingCTIS2024-513998-48-00

Universitair Ziekenhuis BrusselVolutary women who wish to donate their oocytes

Start: 2023-02-02Target: 50Updated: 2024-07-31